Información:
Error:
ID
34429
Descripción
LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib; ODM derived from: https://clinicaltrials.gov/show/NCT02040870
Link
https://clinicaltrials.gov/show/NCT02040870
Palabras clave
Versiones (1)
- 17/1/19 17/1/19 -
Titular de derechos de autor
see on clinicaltrials.gov
Subido en
17 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Non-Small Cell Lung Cancer NCT02040870
Eligibility Non-Small Cell Lung Cancer NCT02040870
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer NCT02040870
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
histologically or cytologically confirmed diagnosis of nsclc that carries an alk rearrangement defined as positive using the fda approved vysis alk break apart fish probe kit (abbott molecular inc.) test and scoring algorithm (including positivity criteria) or positive as assessed by the cfda approved immunohistochemistry (ihc) test (ventana medical systems, inc)
boolean
ID.2
Item
age 18 years or older at the time of informed consent.
boolean
ID.3
Item
patients must have stage iiib or iv nsclc at the time of study entry and have had progressive disease during or after crizotinib treatment whether or not previously treated with cytotoxic chemotherapy. if treated with chemotherapy, maximum 2 lines are allowed.
boolean
ID.4
Item
patients with known hypersensitivity to any of the excipients of ldk378
boolean
ID.5
Item
patients with symptomatic central nervous system (cns) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage cns symptoms
boolean
ID.6
Item
history of carcinomatous meningitis
boolean
ID.7
Item
presence or history of a malignant disease other than nsclc that has been diagnosed and/or required therapy within the past 3 years.
boolean
ID.8
Item
clinically significant, uncontrolled heart disease.
boolean